Titan Biotech 34th AGM Highlights

Titan Biotech Ltd convened its 34th Annual General Meeting on September 29, 2026, via video conferencing.
The agenda included critical proposals for a bonus equity issue and an increase in authorized share capital.

Reader Takeaway: Bonus issue and capital expansion proposals were tabled; await official voting results for final confirmation.

What just happened

The company held its AGM with 256 shareholders participating through virtual means. The agenda covered ten specific business items, ranging from the adoption of FY2026 audited financial statements and dividend declarations to key special resolutions including bonus issue approval and authorization for new loans. Two directors, Ms. Supriya Singla and Mr. Shivom Singla, were proposed for re-appointment, and Mr. Rohit Jain was proposed for a second term as an Independent Director.

Why this matters

The inclusion of a bonus issue proposal is a significant development for current shareholders, signaling potential capital restructuring. The simultaneous proposal to increase authorized share capital provides the necessary headroom for the company to support its future growth and operational funding, including the authorization for new borrowing and property mortgaging.

What changes now

Following the conclusion of the meeting, the company is tasked with finalizing the Scrutinizer's Report. Under SEBI Listing Regulations, these results will be formally communicated to BSE Limited and published on the company's website. Until the official filing of the voting results, the status of the special business resolutions remains pending.

What to track next

Investors must watch for the subsequent regulatory filing confirming the exact ratio of the bonus issue and the final vote count for the authorized capital increase. These details will determine the immediate impact on equity dilution and capital structure.